Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc

Bullboard Posts

Comment by 2019champson Nov 09, 2020 1:38pm

104 Views

Post# 31863970

RE:Mass Testing

Great post arbour. Alot of selling today, not just in arch but all of biotech involving corona plays. Metablok is an inflammation drug not a vaccine. It isnt your typical corona play. I dont get the mass selling. Either way we have bounced back pretty nicely. Weak hands out. Great buying opportunity.

Bullboard Posts

From now on, dynaCERT instead of Bitcoin or NVIDIA?